Abstract
Abstract
Background
New imaging modalities such as IVUS had improved results of stenting of the unprotected left main coronary artery (UPLM). The results of stenting UPLM without these new modalities but with meticulous care need to be studied more.
Methods
We analyzed data from 120 patients with UPLMD of > 50% subjected to stenting. All were stented by drug-eluting stents and followed for six months.
Results
92 patients (77.3%) presented with ACS, of which 65 patients (54.6%) had no Previous Intervention, and 27 patients (22.7%) had a previous PCI. Left ventricular ejection fraction significantly correlates with complication, at 6 months follow up; all 16 patients with reported complications (100%) had baseline LVEF of < 40% (P-value = 0.023). Syntax score: 11 patients (55%) with a high score of more than 32 had adverse events, P = 0.004. Residual syntax shows a less significant correlation with a mean value of 7.3 in the complication group versus 4.9 in the other group (P = 0.016). Final kissing balloon inflation shows no statistically significant difference.
Conclusions
PCI in UPLM is a safe, feasible option with a high technical success rate and acceptable outcome at follow-up even without the utilization of IVUS
Publisher
Research Square Platform LLC
Reference34 articles.
1. Jennifer S, Lawton, Jang B, Jaswal. Jacqueline E, Tamis-Holland PA, Kurlansky, Roxana Mehran, 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. JACC VOL. 79, NO. 2, 2022.
2. 2018 ESC/EACTS Guidelines on myocardial revascularization;Neumann F-J;Eur Heart J,2019
3. Long-term clinical outcome after fractional flow reserve-guided treatment in patients with angiographically equivocal left main coronary artery stenosis;Hamilos M;Circulation,2009
4. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI;Davies JE;N Engl J Med,2017
5. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial;Morice MC;Circulation,2010